综述心血管疾病药物遗传学研究进展及其对临床意义的影响。

IF 4.7 2区医学 Q1 GENETICS & HEREDITY

NPJ Genomic Medicine Pub Date : 2025-07-10 DOI:10.1038/s41525-025-00511-6

Ayat Shorbaji, Peter Natesan Pushparaj, Ayat B Al-Ghafari, Loubna Siraj Mira, Mohammad Abdullah Basabrain, Muhammad Imran Naseer, Farid Ahmed, Muhammad Abu-Elmagd, Mahmood Rasool, Sherin Bakhashab

{"title":"综述心血管疾病药物遗传学研究进展及其对临床意义的影响。","authors":"Ayat Shorbaji, Peter Natesan Pushparaj, Ayat B Al-Ghafari, Loubna Siraj Mira, Mohammad Abdullah Basabrain, Muhammad Imran Naseer, Farid Ahmed, Muhammad Abu-Elmagd, Mahmood Rasool, Sherin Bakhashab","doi":"10.1038/s41525-025-00511-6","DOIUrl":null,"url":null,"abstract":"Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and β-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.","PeriodicalId":19273,"journal":{"name":"NPJ Genomic Medicine","volume":"10 1","pages":"54"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246195/pdf/","citationCount":"0","resultStr":"{\"title\":\"A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.\",\"authors\":\"Ayat Shorbaji, Peter Natesan Pushparaj, Ayat B Al-Ghafari, Loubna Siraj Mira, Mohammad Abdullah Basabrain, Muhammad Imran Naseer, Farid Ahmed, Muhammad Abu-Elmagd, Mahmood Rasool, Sherin Bakhashab\",\"doi\":\"10.1038/s41525-025-00511-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and β-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.\",\"PeriodicalId\":19273,\"journal\":{\"name\":\"NPJ Genomic Medicine\",\"volume\":\"10 1\",\"pages\":\"54\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246195/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Genomic Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41525-025-00511-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Genomic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41525-025-00511-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

摘要

药物遗传学可以通过根据基因谱定制药物治疗和尽量减少试错方法来增强心血管疾病（CVD）的治疗。遗传变异影响对常见心血管疾病药物的反应，包括抗血小板药物（氯吡格雷和阿司匹林）、抗凝剂（华法林）、他汀类药物和抗高血压药物（ACE抑制剂和β受体阻滞剂）。了解遗传多态性可以提高疗效和安全性。尽管取得了这些进展，但还需要进一步的研究来优化药物基因组学应用和推进个体化治疗，以改善心血管疾病的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.

Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and β-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Genomic Medicine Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

9.40

自引率

1.90%

发文量

审稿时长

17 weeks

期刊介绍： npj Genomic Medicine is an international, peer-reviewed journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine. The journal defines genomic medicine as "diagnosis, prognosis, prevention and/or treatment of disease and disorders of the mind and body, using approaches informed or enabled by knowledge of the genome and the molecules it encodes." Relevant and high-impact papers that encompass studies of individuals, families, or populations are considered for publication. An emphasis will include coupling detailed phenotype and genome sequencing information, both enabled by new technologies and informatics, to delineate the underlying aetiology of disease. Clinical recommendations and/or guidelines of how that data should be used in the clinical management of those patients in the study, and others, are also encouraged.